Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders.
作者信息
Knollmann Björn C
出版信息
Heart Rhythm. 2010 Nov;7(11):1683-5. doi: 10.1016/j.hrthm.2010.07.028. Epub 2010 Jul 29.
Abstract
摘要
相似文献
1
Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders.
Heart Rhythm. 2010 Nov;7(11):1683-5. doi: 10.1016/j.hrthm.2010.07.028. Epub 2010 Jul 29.
2
Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.
Heart Rhythm. 2010 Nov;7(11):1676-82. doi: 10.1016/j.hrthm.2010.07.004. Epub 2010 Jul 8.
3
Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
JAMA Cardiol. 2017 Jul 1;2(7):759-766. doi: 10.1001/jamacardio.2017.1320.
4
Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Heart Rhythm. 2013 Apr;10(4):542-7. doi: 10.1016/j.hrthm.2012.12.035. Epub 2012 Dec 31.
5
Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Europace. 2011 Jun;13(6):897-901. doi: 10.1093/europace/euq517. Epub 2011 Feb 2.
6
In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
J Physiol. 2016 Feb 1;594(3):567-93. doi: 10.1113/JP271282. Epub 2015 Dec 30.
7
Pharmacological treatment of electrical storm in cathecolaminergic polymorphic ventricular tachycardia.
Pacing Clin Electrophysiol. 2010 Mar;33(3):e27-31. doi: 10.1111/j.1540-8159.2009.02586.x. Epub 2009 Nov 2.
8
Does β-Blockade for Treatment of Refractory Ventricular Fibrillation or Pulseless Ventricular Tachycardia Improve Outcomes?
Ann Emerg Med. 2020 Jul;76(1):42-45. doi: 10.1016/j.annemergmed.2020.01.025. Epub 2020 Mar 16.
9
Catecholaminergic Ventricular Tachycardia, Pregnancy and Teenager: Are They Compatible?
Pediatr Cardiol. 2015 Oct;36(7):1542-7. doi: 10.1007/s00246-015-1232-3. Epub 2015 Aug 18.
10
A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia.
Pacing Clin Electrophysiol. 2019 Aug;42(8):1146-1154. doi: 10.1111/pace.13668. Epub 2019 Apr 17.
引用本文的文献
1
Neuronal Na Channels Are Integral Components of Pro-arrhythmic Na/Ca Signaling Nanodomain That Promotes Cardiac Arrhythmias During β-adrenergic Stimulation.
JACC Basic Transl Sci. 2016 Jun;1(4):251-266. doi: 10.1016/j.jacbts.2016.04.004.
2
Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release.
Cardiovasc Res. 2015 Apr 1;106(1):143-52. doi: 10.1093/cvr/cvu262. Epub 2014 Dec 23.
3
Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Heart Rhythm. 2013 Apr;10(4):542-7. doi: 10.1016/j.hrthm.2012.12.035. Epub 2012 Dec 31.
4
Calsequestrin 2 and arrhythmias.
Am J Physiol Heart Circ Physiol. 2012 Mar 15;302(6):H1250-60. doi: 10.1152/ajpheart.00779.2011. Epub 2011 Dec 23.
5
Genetics of sudden cardiac death syndromes.
Curr Opin Cardiol. 2011 May;26(3):196-203. doi: 10.1097/HCO.0b013e3283459893.
6
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Circ Arrhythm Electrophysiol. 2011 Apr;4(2):128-35. doi: 10.1161/CIRCEP.110.959916. Epub 2011 Jan 26.
本文引用的文献
1
Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Heart Rhythm. 2013 Apr;10(4):542-7. doi: 10.1016/j.hrthm.2012.12.035. Epub 2012 Dec 31.
2
Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
J Mol Cell Cardiol. 2010 Feb;48(2):293-301. doi: 10.1016/j.yjmcc.2009.10.005. Epub 2009 Oct 14.
3
Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
Circulation. 2009 May 12;119(18):2426-34. doi: 10.1161/CIRCULATIONAHA.108.829267. Epub 2009 Apr 27.
4
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
Nat Med. 2009 Apr;15(4):380-3. doi: 10.1038/nm.1942. Epub 2009 Mar 29.
5
Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model.
Circ Res. 2008 Aug 1;103(3):298-306. doi: 10.1161/CIRCRESAHA.108.171660. Epub 2008 Jun 26.
6
A genetic framework for improving arrhythmia therapy.
Nature. 2008 Feb 21;451(7181):929-36. doi: 10.1038/nature06799.
7
Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Heart Rhythm. 2007 Sep;4(9):1149-54. doi: 10.1016/j.hrthm.2007.05.017. Epub 2007 May 24.
8
Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.
J Clin Invest. 2007 Jul;117(7):1814-23. doi: 10.1172/JCI31080.
9
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia.
J Clin Invest. 2006 Sep;116(9):2510-20. doi: 10.1172/JCI29128. Epub 2006 Aug 24.
10
Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model.
Circ Res. 2006 Aug 4;99(3):292-8. doi: 10.1161/01.RES.0000235869.50747.e1. Epub 2006 Jul 6.
Zotero 插件